300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Construction
Mobile
Oil and Gas
Payments
Retail
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Celebrity
Fashion
Infrastructure
Social
Food and Beverage
Life Science
Publishing
Cannabis
Wine and Spirits
Mobile Apps
LGBT
Real Estate
Sporting Goods
Music
Climate
Art
Finance
Manufacturing
Social Media
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Enterprise
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Oceania
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Argentina
Tunisia
Taiwan
Zimbabwe
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Paraguay
Seychelles
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Bangladesh
Barbados
Belgium
Angola
Austria
Europe
Ethiopia
Jordan
Cyprus
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Qatar
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
naturalX Health Ventures, VC Fund

naturalX Health Ventures

VC Fund

Berlin, Germany

NaturalX Health Ventures is an investment company of Schwabe Group that focuses its investment in consumer health companies. The company strives to merge the growth opportunities of youthful and innovative businesses with the financial stability and diverse expertise provided by our parent company.NaturalX Health Ventures invests across variousstages from seed to late, with a primary emphasis on series A and series B investments, indicating a robust indication of product-market fit. The firm's focus centers on innovations at the crossroads of natural and digital health.

Total investments:
6
Last investment:
Lead investor:
17%
Fund size:
$105M
Last fund:

Last updated:

Industries naturalX Health Ventures invests in

Health CareWearablesMedical DeviceHealth DiagnosticsMedical

Stages naturalX Health Ventures invests in

Series ASeries BConvertible Note

Countries naturalX Health Ventures invests in

SwitzerlandPolandSweden

Round sizes

Series A $5.9M–$28M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$5.9M–$28M

Investment Focus

Industry

  • Health Care 6 (100%)
  • Wearables 2 (33%)
  • Medical Device 2 (33%)
  • Health Diagnostics 2 (33%)
  • Medical 1 (17%)
See all 8 industries →

Stage

  • Series A 4 (67%)
  • Series B 1 (17%)
  • Convertible Note 1 (17%)

Country

  • Switzerland 3 (50%)
  • Poland 1 (17%)
  • Sweden 1 (17%)

Team

NameTitleInvestmentsLinksEmail
Marvin Amberg
Marvin Amberg Managing Director
Managing Director Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Ilant Health provides treatment for obesity and weight management. $15M / Series A / Apr 09, 2026
Jutro Medical offers a combination of online and offline primary care — pairing mobile first telemedicine with physical clinic $28.2M / Series A / Dec 16, 2025
Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. $42M / Series B / May 01, 2025
Kyan Health is the first Swiss digital health company to provide end-to-end, fully personalized, evidence-based mental wellbeing and health solutions for employees and their families. The company's mission is to create a frictionless experience when accessing and engaging with mental health and wellbeing support services at work – fromemployee engagement and awareness creation over self-improvement and self-care to coaching and counseling. $12.7M / Series A / Nov 26, 2024
Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry. Convertible Note / Jul 18, 2024
mybacs is a DTC, research-driven, Biotechnology company specialized in the human microbiome. Our goal is to revolutionize the market around intestinal healthcare and thus make a decisive contribution to the daily well-being of our customers. Our team of pharmaceutical scientists and physicians is focused on the development of innovative andhighly-dosed synbiotic supplements. These are aligned by our singular formulations from specifically selected probiotic cultures, prebiotics as well as minerals and vitamins tailored to the individual needs of our customers. $5.9M / Series A / Oct 19, 2023

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Construction
Mobile
Oil and Gas
Payments
Retail
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Celebrity
Fashion
Infrastructure
Social
Food and Beverage
Life Science
Publishing
Cannabis
Wine and Spirits
Mobile Apps
LGBT
Real Estate
Sporting Goods
Music
Climate
Art
Finance
Manufacturing
Social Media
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Enterprise
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Oceania
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Argentina
Tunisia
Taiwan
Zimbabwe
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Paraguay
Seychelles
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Bangladesh
Barbados
Belgium
Angola
Austria
Europe
Ethiopia
Jordan
Cyprus
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Qatar
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does naturalX Health Ventures invest in?

naturalX Health Ventures invests primarily in Health Care, Wearables and Medical Device startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does naturalX Health Ventures invest in?

naturalX Health Ventures typically joins rounds of $5.9M–$28M at Series A. These are whole funding-round sizes, not naturalX Health Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds naturalX Health Ventures took part in.

How do I contact naturalX Health Ventures?

Public channels for naturalX Health Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at naturalX Health Ventures?

The team at naturalX Health Ventures includes Marvin Amberg (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
naturalX Health Ventures naturalX Health Ventures Find emails